A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design (Q44471060)

3 December 2017

A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design (English)

1 reference

3 December 2017

phase I clinical trial

0 references

author name string

Gadgeel SM

1

1 reference

3 December 2017

Boinpally RR

2

1 reference

3 December 2017

Heilbrun LK

3

1 reference

3 December 2017

Wozniak A

4

1 reference

3 December 2017

Jain V

5

1 reference

3 December 2017

Redman B

6

1 reference

3 December 2017

Zalupski M

7

1 reference

3 December 2017

Wiegand R

8

1 reference

3 December 2017

Parchment R

9

1 reference

3 December 2017

LoRusso PM

10

1 reference

3 December 2017

1 February 2003

1 reference

Investigational New Drugs

3 December 2017

1 reference

3 December 2017

21

1 reference

3 December 2017

1

1 reference

3 December 2017

63-74

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1022972427532

3 December 2017

0 references

cites work

Structure-antitumor activity relationship of semi-synthetic spicamycin analogues

1 reference

12 December 2020

Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells

1 reference

12 December 2020

Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles.

1 reference

12 December 2020

Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study

1 reference

12 December 2020

Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines

1 reference

12 December 2020

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro

1 reference

12 December 2020

Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma

1 reference

12 December 2020

[Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500]

1 reference

12 December 2020

KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells

1 reference

12 December 2020

Chronotherapy of colorectal cancer metastases

1 reference

12 December 2020

Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts

1 reference

12 December 2020

Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen

1 reference

12 December 2020

Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein

1 reference

12 December 2020

Therapeutic implications of circadian rhythms in cancer patients

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells

1 reference

12 December 2020

KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1022972427532

1 reference

Dimensions Publication ID

3 December 2017

0 references

1 reference